

March 4, 1970

Mr. Herb Sturz
Vera Institute
30 East 39th Street
New York, New York

Dear Mr. Sturz:

Enclosed is a draft proposal dated November 27, 1969, which describes our suggestion to the National Institutes of Mental Health and to the New York State Narcotic Addiction Control Commission for the development of a long acting narcotic antagonist.

Since formulating the proposal we have had additional experience with cyclazocine which makes us believe that the same principles and techniques should be applied to the development of a long acting form for cyclazocine as well.

For either naloxone or cyclazocine, the first step is the development of a slow release form and a determination of a maximum amount that can be concentrated in a silastic vehicle. The initial animal trials must be undertaken to determine the release rate. These pharmacological assays can be done by a number of American consulting firms. If this formulation is successful, then concurrent animal and human trials must be undertaken in the animals for toxicity purposes and in humans for toxicity and the determination of the duration of antagonism.

The funds requested are for the pharmacological feasibility only. If such actions appear logical to you and your committee, my associates and I would be pleased to cooperate in any way possible.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp

enc.